Crossmark

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome

Crossref DOI link: https://doi.org/10.1007/s10637-022-01315-6

Published Online: 2023-04-01

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nguyen, Christopher N.

Iyer, Swaminathan P.

Duvic, Madeleine

Barde, Prajak J.

Nair, Ajit

Routhu, Kasi Viswanath

Huen, Auris O.
Funding

Funding for this research was provided by:

Rhizen Pharmaceuticals
License Information

Text and Data Mining valid from 2023-04-01

Version of Record valid from 2023-04-01
More Information

Article History

Received: 6 September 2022

Accepted: 18 October 2022

First Online: 1 April 2023

Declarations

:

: The authors declare no competing interests.

: The authors report there are no competing interests to declare.

Document is current

Any future updates will be listed below